14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $52.14 $64.31 Friday, 3rd May 2024 IMCR stock ended at $60.23. This is 1.29% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 4.90% from a day low at $59.33 to a day high of $62.24.
90 days $52.14 $76.15
52 weeks $42.23 $76.98

Historical Immunocore Holdings plc prices

Date Open High Low Close Volume
May 03, 2024 $59.50 $62.24 $59.33 $60.23 371 808
May 02, 2024 $59.66 $60.90 $58.76 $59.46 394 006
May 01, 2024 $58.92 $60.20 $58.75 $59.05 506 787
Apr 30, 2024 $58.05 $60.14 $57.93 $59.08 333 398
Apr 29, 2024 $58.58 $60.02 $57.60 $58.10 532 574
Apr 26, 2024 $57.75 $58.87 $56.10 $58.46 402 526
Apr 25, 2024 $58.37 $59.41 $57.34 $58.00 401 183
Apr 24, 2024 $57.25 $58.58 $55.92 $58.47 394 870
Apr 23, 2024 $56.40 $57.98 $56.25 $57.31 298 691
Apr 22, 2024 $56.11 $57.30 $55.60 $55.82 206 385
Apr 19, 2024 $54.52 $56.06 $53.79 $55.68 440 727
Apr 18, 2024 $55.09 $55.09 $52.72 $54.74 426 497
Apr 17, 2024 $53.37 $55.08 $52.14 $54.58 473 234
Apr 16, 2024 $55.38 $55.50 $53.21 $53.37 646 875
Apr 15, 2024 $56.53 $57.17 $55.46 $55.54 287 891
Apr 12, 2024 $59.07 $59.07 $56.33 $56.53 350 696
Apr 11, 2024 $59.15 $60.01 $58.03 $59.07 352 374
Apr 10, 2024 $57.26 $59.49 $55.68 $58.81 566 984
Apr 09, 2024 $60.92 $61.06 $57.65 $58.08 680 767
Apr 08, 2024 $63.92 $63.94 $60.00 $60.50 250 869
Apr 05, 2024 $62.90 $64.10 $62.50 $63.50 205 587
Apr 04, 2024 $63.80 $64.11 $62.20 $62.21 334 022
Apr 03, 2024 $63.49 $64.31 $62.93 $63.75 148 670
Apr 02, 2024 $62.77 $63.78 $61.88 $63.48 562 597
Apr 01, 2024 $65.77 $66.00 $62.81 $62.94 626 200
Click to get the best stock tips daily for free!

About Immunocore Holdings plc

Immunocore Holdings plc Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (N... IMCR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT